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Abstract
The -945GC polymorphism (rs6918698) in the connective tissue growth factor gene promoter (CTGF/CCN-2) has
been associated with end organ damage in systemic sclerosis. Because CTGF is important in progression of
diabetic kidney disease, we investigated whether the -945GC polymorphism is associated with plasma CTGF level
and outcome in type 1 diabetes.
The study cohort consisted of 448 diabetic nephropathy patients and 419 normoalbuminuric diabetic patients with
complete data concerning renal function and cardiovascular characteristics. Genomic DNA was genotyped by a
QPCR-based SNP assay. We observed no relation between the -945GC polymorphism and plasma CTGF level, and
the genotype frequencies were not different in nephropathy patients vs. normoalbuminuric controls. General and
cardiovascular mortality, and renal function decline was similar in patients with CC, CG or GG genotypes.
In conclusion, the -945GC SNP does not affect plasma CTGF levels, incidence and prognosis of diabetic
nephropathy, and cardiovascular outcome.
Findings
Connective tissue growth factor (CTGF/CCN-2) is a key
peptide mediating organ fibrosis [1-3]. Fonseca et al.
identified a single nucleotide polymorphism (SNP) at
position -945 upstream from the transcription initiation
site of the CTGF gene (-945GC) overrepresented in
patients with systemic sclerosis (SSc) and associated
with a higher incidence of lung fibrosis [4]. Subsequent
studies have either confirmed or questioned the associa-
tion of the G allele with incidence and severity of SSc,
and its relation with in vivo CTGF expression levels has
not been studied to date [5,6]. Also in diabetic nephro-
pathy, CTGF is an important pathogenic factor, and
plasma CTGF levels independently predict mortality and
end-stage renal disease (ESRD) [7]. A recent study in
hemodialysis patients indicated that the -945GC poly-
morphism might be associated with cardiovascular, but
not all-cause mortality [8]. Therefore, we examined the
possible relevance of the -945GC polymorphism for
plasma CTGF levels, and for nephropathy and asso-
ciated manifestations in patients with type 1 diabetes.
General characteristics and baseline parameters of
patients are summarized in Table 1.
Smoking and body mass index (BMI) did not differ
significantly between diabetic nephropathy and normoal-
buminuric subjects. Retinopathy, blood pressure, use of
antihypertensive medication, and parameters of nephro-
pathy were all higher in the diabetic nephropathy group
as compared to the normoalbuminuric subjects.
Genomic DNA was genotyped by a Custom-Taqman-
SNP-Genotyping-Assay (Applied Biosystems, Foster
City, CA, USA) for the GC polymorphism at position
-945. The distributions of the genotypes were in accor-
dance with the Hardy-Weinberg equilibrium for the
entire population (p = 0.52), and the subgroups divided
by presence or absence of nephropathy (p = 0.49 and
p = 0.10 respectively). Genotype frequencies were very
similar between diabetic nephropathy and diabetic nor-
moalbuminuric patients, with a frequency of the G allele
of 22.8% in the DN group as compared to 21.9% in the
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NA group (p = 0.481) (Table 2). The power of the study
was determined using web-based software (http://www.
stat.ubc.ca/~rollin/stats/ssize/b2.html). This showed a
power of 95% for detection of a 10% increase in DN
patients of the GG genotype frequency, i.e. an increase to
31.9% in DN as compared to the 21.9% in the NA patients
which was comparable with the previously observed range
of 30 to 20% in diseased vs. control groups [4].
Plasma CTGF levels were determined in a subset of 381
by a sandwich enzyme-linked immunosorbent assay
(ELISA) using monoclonal antibodies against two distinct
epitopes of human CTGF (FibroGen, San Francisco, CA)
as described previously [7]. Diabetic nephropathy
was associated with significantly elevated CTGF levels
(381.3 pmol/l (270.3-626.4) in DN vs. 235.2 pmol/l (168.1-
352.9) in normoalbuminuria, p < 0.0001). However, there
was no difference in CTGF levels between genotypes
(Figure 1). Also, linear regression analysis could not pre-
dict plasma CTGF levels from genotype (not shown).
The mean follow-up time in the diabetic nephropathy
group was comparable to that in the normoalbuminuric
group, 9.0 ± 3.3 and 8.6 ± 3.2 years, respectively. At
follow-up, the presence of renal and cardiovascular end-
points was compared with genotype. There were no
Table 1 Patient characteristics at baseline
Diabetic Nephropathy Normoalbuminuria P-value
Patient characteristics
N (% male) 448 (60.9) 419 (54.4) p = 0.02
Age (years) 42.2 ± 10.5 45.3 ± 11.5 p < 0.001
Duration of DM (years) 28.2 ± 8.7 27.8 ± 10.1 p = 0.025
BMI (kg/m2) 24.2 ± 3.3 24.1 ± 2.9 p = 0.7
Retinopathy (nil/simplex/proliferative) 7/135/306 151/159/109 p < 0.001
Antihypertensiva (no/yes) 95/308 351/68 p < 0.001
Smokers (%) 46 39 p = 0.05
Glycemic control
Blood glucose (mmol/l) 11.0 ± 5.4 9.4 ± 4.7 p < 0.001
HbA1c (%) 9.4 ± 1.5 8.4 ± 1.1 p < 0.001
Parameters of Nephropathy
UAE (mg/24 h) 593.1 (250.0-1519.5) 7.0 (4.0-12.0) p < 0.001
Plasma creatinine (μmol/l) 102 (82.0-136.3) 79 (53-81) p < 0.001
GFR (ml/min/1.73 m2) 66.1 ± 27.7 87.4 ± 14.9 p < 0.001
ESRD (%male) 24 (70.8) 0 p < 0.001
Systolic Blood Pressure (mm Hg) 144.3 ± 21.8 133.8 ± 18.6 p < 0.001
Diastolic Blood Pressure (mm Hg) 82.5 ± 12.2 76.1 ± 9.6 p < 0.001
Data are presented as mean ± SD, median (interquartile range), or N (%). The study was performed according to the principles of the Declaration of Helsinki and
approved by the ethical committee of Copenhagen County. All patients gave informed consent.
Table 2 Distribution of genotype and allele frequencies for the CTGF promoter polymorphism at -945
Genotype frequencies (%) Total P-value
CTGF -945GC polymorphism Diabetic Nephropathy Normoalbuminuria
CC 126 (28.1) 126 (30.1) 252 (29.0) 0.481
CG 220 (49.1) 201 (48.0) 421 (48.6)
GG 102 (22.8) 92 (21.9) 194 (22.4)
Total 448 (100) 448 (100) 867 (100)
Allele frequencies (%) Odds ratio P-value
CTGF -945 promoter polymorphism Diabetic Nephropathy Normoalbuminuria
Allele C 472 (52.7) 453 (54.0) 1.057 0.596
Allele G 424 (47.3) 385 (46.0)
P-values were calculated using Fisher’s exact test and Chi-square analysis respectively. There is no difference in genotype or allele frequencies between diabetic
nephropathy patients and normoalbuminuric patients at baseline.
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significant differences between the CC, CG and GG geno-
types in terms of mortality or development of ESRD in the
total population under study (Table 3). Also, in separate
analyses of normoalbuminuric patients and patients with
nephropathy there was no difference in incidence of
ESRD, total mortality, cardiovascular mortality, or non-
fatal cardiovascular events between the different genotypes
(all p > 0.05). None of the normoalbuminuric patients
developed ESRD over the studied period.
Altogether, this makes it doubtful that the -945GC
polymorphism plays a major role in susceptibility to
developing DN. Apparently, the association of the CTGF
-945GC SNP with disease is not the same in all patient
groups and categories, as has been noted in previous stu-
dies that could not always confirm the originally observed
association of the -945GC SNP with Ssc [4,5]. Although,
theoretically, population differences might affect the
apparent contribution of SNPs to disease manifestations,
one of these reports examined a large number of patients
of diverse nationality and ethnicity but could not repli-
cate the association of the G allele with SSc [6].
It has been observed that CTGF levels are higher in
Ssc patients as compared to healthy controls [9], but a
possible association of serum or plasma CTGF levels
with genotype has not been assessed. This hampers an
adequate interpretation of the effect of the polymorph-
ism on in vivo CTGF transcription and translation.
Therefore, we compared genotype differences for the
-945CG polymorphism with plasma CTGF levels in DN
and NA patients with diabetes. We found that plasma
CTGF levels were not associated with this polymorph-
ism, which further questions its relevance in diabetic
kidney disease. In contrast, it has recently been shown
that the G allele of an SNP (with a population frequency
of around 5%) at -20 in the promoter region of the
































Figure 1 Relation of plasma CTGF levels (pmol/l) with
genotype. Bars are median+interquartile range. White bars:
normoalbuminuric diabetic patients (N = 173); black bars: diabetic
patients with nephropathy (N = 198). Plasma CTGF levels are higher
in DN (p < 0.0001, ANOVA on log transformed values for conversion
to a normal distribution of positively skewed data). There is no
significant difference in plasma levels according to genotype.
Number of patients in each group is indicated in italics above the
error bars.
Table 3 Association of the CTGF promoter polymorphism at -945 with clinical outcomes at follow-up
CC (%) CG (%) GG (%) Total (%) P-value
Diabetic nephropathy Mortality Yes 42 (30) 62 (44) 36 (26) 140 (100) 0.369
No 84 (27) 158 (51) 66 (22) 308 (100)
Cardiovascular (CV) death Yes 20 (27) 35 (48) 18 (25) 73 (100) 0.915
No 106 (28) 185 (49) 84 (23) 375 (100)
Non-fatal CV event Yes 40 (35) 50 (43) 25 (22) 115 (100) 0.173
No 86 (26) 170 (51) 77 (23) 333 (100)
End-stage renal failure Yes 29 (30) 46 (47) 23 (23) 98 (100) 0.886
No 97 (28) 174 (50) 79 (22) 350 (100)
Normoalbuminuria Mortality Yes 14 (40) 15 (43) 6 (17) 35 (100) 0.394
No 112 (29) 186 (48) 86 (22) 384 (100)
Cardiovascular (CV) death Yes 4 (31) 6 (46) 3 (23) 13 (100) 0.991
No 122 (30) 195 (48) 89 (22) 406 (100)
Non-fatal CV event Yes 15 (37) 20 (49) 6 (14) 41 (100) 0.415
No 111 (29) 181 (48) 86 (23) 378 (100)
Microalbuminuria Yes 21 (38) 25 (45) 9 (16) 55 (100) 0.306
No 105 (29) 176 (48) 83 (23) 364 (100)
Development of nephropathy Yes 0 (0) 1 (100) 0 (0) 1 (100) 0.581
No 126 (30) 200 (48) 92 (22) 418 (100)
There is no effect of the -945GG genotype on either mortality, fatal or non-fatal cardiovascular events, or development of renal disease. P-values are calculated
using Fisher’s exact test.
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towards developing micro- and macroalbuminuria via
increased CTGF promoter activity depending on Smad1
[10]. It will be interesting to learn whether this SNP
affects plasma CTGF levels.
Studies regarding other SNPs in the CTGF promoter
have been published before, and most of these deny a
contribution of CTGF SNPs to human disease. Three
other potentially functional SNPs in the CTGF gene (at
positions -650, -484 and 247) have been reported not to
be associated with diabetic nephropathy [11]. A large
study using transmission equilibrium testing revealed no
relationship with diabetic nephropathy at yet another
SNP (rs9493150) in the CTGF gene [12]. In a study
from Thailand, an SNP at position -447 was analysed in
the context of biliary atresia and no association was
observed with either incidence of biliary atresia or
occurrence of postoperative jaundice [13]. Finally, none
of six CTGF gene polymorphisms (including the
-945GC SNP) studied in chronic hepatitis C infection
was associated with the severity of hepatic fibrosis [14].
However, a recent study in a French population did
show that the frequency of the rs9399005TT genotype
was lower in Ssc than in control patients, and that the
T allele was associated with altered mRNA stability [15].
This is an interesting finding awaiting validation in inde-
pendent studies of Ssc patients, given the large discre-
pancies between different studies on polymorphisms
even in the same disease. To conclude, in our cohort of
867 Northern European type 1 diabetes patients, the
previously described -945GC SNP appears not to have a
major impact on plasma CTGF levels, incidence and
prognosis of nephropathy, and cardiovascular outcome.
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